Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark P Fereshteh

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cancer Research|May 17, 2008
The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in miceMark P Fereshteh, Maddalena T Tilli, Sung Eun Kim, et al.
Plos One|April 17, 2014
Targeted disruption of β-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growthJonathan W Kotula, Jinpeng Sun, Margie Li, et al.
SLAS Discovery : Advancing Life Sciences R & D|June 7, 2018
Miniaturized High-Throughput Multiparameter Flow Cytometry Assays Measuring In Vitro Human Dendritic Cell Maturation and T-Cell Activation in Mixed Lymphocyte ReactionsYi Fan, Joseph G Naglich, Jennifer D Koenitzer, et al.
Molecular and Cellular Biology|September 4, 2008
Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cellsAnnabell S Oh, John T Lahusen, Christopher D Chien, et al.
ACS Central Science|May 11, 2016
Antroquinonol A: Scalable Synthesis and Preclinical Biology of a Phase 2 Drug CandidateMatthew T Villaume, Eran Sella, Garrett Saul, et al.
Journal of Biomolecular Screening|May 5, 2016
Development of a Human Whole Blood Screening Platform to Monitor JAK/STAT Signaling Using High-Throughput Flow CytometryMark P Fereshteh, Xin Li, Sha Li, et al.
ACS Medicinal Chemistry Letters|November 16, 2018
Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology AgentsYong Zhang, Yufen Zhao, Andrew J Tebben, et al.
ACS Medicinal Chemistry Letters|February 20, 2020
Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology AgentUpender Velaparthi, Chetan Padmakar Darne, Jayakumar Warrier, et al.
ACS Medicinal Chemistry Letters|July 18, 2020
Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of PsoriasisSatheesh Nair, Sreekantha Ratna Kumar, Venkatram Reddy Paidi, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cancer Research|May 17, 2008
The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in miceMark P Fereshteh, Maddalena T Tilli, Sung Eun Kim, et al.
Plos One|April 17, 2014
Targeted disruption of β-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growthJonathan W Kotula, Jinpeng Sun, Margie Li, et al.
SLAS Discovery : Advancing Life Sciences R & D|June 7, 2018
Miniaturized High-Throughput Multiparameter Flow Cytometry Assays Measuring In Vitro Human Dendritic Cell Maturation and T-Cell Activation in Mixed Lymphocyte ReactionsYi Fan, Joseph G Naglich, Jennifer D Koenitzer, et al.
Molecular and Cellular Biology|September 4, 2008
Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cellsAnnabell S Oh, John T Lahusen, Christopher D Chien, et al.
ACS Central Science|May 11, 2016
Antroquinonol A: Scalable Synthesis and Preclinical Biology of a Phase 2 Drug CandidateMatthew T Villaume, Eran Sella, Garrett Saul, et al.
Journal of Biomolecular Screening|May 5, 2016
Development of a Human Whole Blood Screening Platform to Monitor JAK/STAT Signaling Using High-Throughput Flow CytometryMark P Fereshteh, Xin Li, Sha Li, et al.
ACS Medicinal Chemistry Letters|November 16, 2018
Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology AgentsYong Zhang, Yufen Zhao, Andrew J Tebben, et al.
ACS Medicinal Chemistry Letters|February 20, 2020
Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology AgentUpender Velaparthi, Chetan Padmakar Darne, Jayakumar Warrier, et al.
ACS Medicinal Chemistry Letters|July 18, 2020
Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of PsoriasisSatheesh Nair, Sreekantha Ratna Kumar, Venkatram Reddy Paidi, et al.
Pageof 1